CA-MICROVENTION
9.7.2024 15:01:30 CEST | Business Wire | Press release
MicroVention, Inc., a global neurovascular company and wholly owned subsidiary of Terumo Corporation, announced the publication of the SOFIA™ Aspiration System as first-line Technique (SOFAST): A prospective, multicenter study to assess the efficacy and safety of the 6 French SOFIA™ Flow Plus Aspiration Catheter for endovascular stroke thrombectomy, recently published in the Journal of NeuroInterventional Surgery (JNIS).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240709802645/en/
MicroVention Announces Clinical Publication of SOFAST: SOFIA™ Aspiration System as First Line Technique in Treating Acute Ischemic Stroke (Graphic: Business Wire)
The SOFAST study assessed the SOFIA™ Flow Plus Aspiration Catheter (SOFIA 6F) for treating acute ischemic stroke caused by large vessel occlusion. This U.S. Prospective, multicenter study involved 108 patients and aimed to confirm the catheter’s safety, speed and effectiveness in revascularization. The long-standing legacy of SOFIA is reinforced by the important data points observed in this publication emphasizing the following:
- Speed: 12-minute median groin puncture to clot contact time and 17-minute median groin puncture to recanalization time.
- Efficacy: 75% First Pass mTICI≥2b using SOFIA 6F.
- Safety: 0% embolization to new territories and symptomatic intracranial hemorrhage rate within 24h.
- Clinical Outcomes: 66.7% of patients experienced good functional outcomes at 90 days.
Please reference the publication for a comprehensive set of data points and outcomes.
“The efficacy and safety data from this prospective, multi-center, independent core-lab adjudicated SOFAST study are very impressive and sets a new innovation standard. High rates of mTICI≥2b (97.2%) revascularization at the procedure end, 70.4% rate of mTICI 2c or better after the first pass, median time to recanalization of 17 minutes and 66.7% rate of good clinical outcomes are amongst the very best metrics reported with contemporary thrombectomy devices,” said Dr. Dheeraj Gandhi, Vice Chairman for Academic Affairs; Director, Interventional Neuroradiology; Director, CMIT Center (Center for Metabolic Imaging and Therapeutics); Professor of Radiology, Neurology and Neurosurgery, University of Maryland School of Medicine.
“The SOFAST Study further underscores that our SOFIA™ Aspiration Catheters have set the standard for more than a decade with its renowned trackability, speed and now with further proven clinical performance,” said Carsten Schroeder, President and CEO, MicroVention, Inc. “We will continue to participate in critical clinical research such as SOFAST, work side-by-side with leading physicians around the world to identify the evolving needs in patient care, and then transform those insights into innovative technologies that help to save patient lives.”
MicroVention also recently celebrated a decade of legacy innovation commemorating the anniversary of SOFIA™ and SOFIA™ Flow Plus Aspiration Catheters, with more than half a million worldwide procedures performed across 170 countries, and 30+ articles published globally since it was first introduced more than ten years ago. Designed for speed to target, clot engagement, kink resistance and a confident first pass, SOFIA Flow Plus Aspiration Catheters continue to set the pace in treating acute ischemic stroke.
From access to revascularization, MicroVention now offers a fully integrated and streamlined portfolio of stroke solutions including SOFIA™, SOFIA™ Flow Plus Aspiration Catheters, as well as ERIC™ Retrieval Device, BOBBY™ Balloon Guide Catheter, WEDGE™ Microcatheter, HEADWAY™ Microcatheters and TRAXCESS™ Guidewires.
About MicroVention, Inc.
Founded in 1997, MicroVention develops and markets medical devices that enable or significantly improve treatment of cerebrovascular diseases. In 2006, Terumo Corporation, a major worldwide medical device company headquartered in Tokyo, Japan, acquired MicroVention into their family of Companies. Terumo’s acquisition of MicroVention allowed both Companies to leverage their unique, proprietary technologies toward an increased focus on treating cerebrovascular diseases. Headquartered in California, MicroVention products are today sold in more than seventy countries through a direct sales organization alongside strategic distribution partnerships. Manufacturing facilities are in Aliso Viejo, California and San José, Costa Rica. For more information on MicroVention, please visit www.microvention.com.
About Terumo Corporation
Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 Associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice. Terumo will further strive to be of value to patients, medical professionals, and society at large. For more information on Terumo, please visit www.terumo.com/about/profile.
** Editor’s Note: For a Clinical Glossary of Terms, please visit https://www.microvention.com/clinical-education/glossary.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240709802645/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Svante and Integrated Packaging Company Advance U.S. Biogenic CDR Project to Feasibility10.3.2026 14:57:00 CET | Press release
The bioenergy with carbon capture (BECCS) project aims to remove more than 500,000 tonnes per year of biogenic CO2 emissions from a U.S. paper mill’s recovery boiler Svante Development Inc. is co-investing to advance the project The project will generate high-quality carbon dioxide removal (CDR) credits to market to Voluntary Carbon Market (VCM) buyers. Svante Technologies Inc. (“Svante”) announced today that its bioenergy with carbon capture and storage (BECCS) project at a paper mill in the Southeast U.S. has progressed to the feasibility study phase. The project is being developed in partnership with an integrated sustainable packaging company, following an extensive screening and pre-feasibility study conducted across several of the partner’s mills. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310319382/en/ During the feasibility study phase, the companies will complete further engineering and design activities, cos
Forbes 40th Annual World’s Billionaires List10.3.2026 14:43:00 CET | Press release
Elon Musk Is World’s Richest Person Ever Recorded Forbes releases its 40th-annual World’s Billionaireslist, the definitive ranking of the planet’s richest people. Wealth surged to unprecedented levels over the past year, with fortunes climbing at a record pace. This year’s list features 3,428 billionaires, the most since the list’s inception in 1987. The world’s wealthiest people are worth a record $20.1 trillion combined, up from $16.1 trillion in 2025. Elon Musktops the Billionaires list for the second year in a row and is the richest person ever recorded, worth an estimated $839 billion. His net worth skyrocketed by half of a trillion dollars from last year, thanks to a rise in the value of Tesla, and SpaceX which is aiming to go public in 2026. Musk is the first person ever recorded to reach the $800 billion mark, as he moves toward becoming the world’s first trillionaire. “It’s the year of the billionaire,” said Chase Peterson-Withorn, Forbes Senior Editor, Wealth. “The planet add
Adtran sets intra-data center benchmark with all-new ultra-low-power LiteWave800™ LPO module10.3.2026 14:00:00 CET | Press release
News summary: AI clusters and GPU fabrics demand massive capacity, yet traditional 800G optics increase energy consumption, heat and cost burdens Adtran’s LiteWave800™ introduces a new class of ultra-low-power, low-latency DR8 LPO modules built on a fully re-engineered design Breakthrough energy efficiency of 1pJ/bit enables greener, scalable intra-data center links for next-generation AI and cloud workloads Adtran today launched LiteWave800™, an ultra‑low‑power 800Gbit/s DR8 linear pluggable optics (LPO) module engineered to help data centers address the power, latency, thermal and bandwidth demands of modern AI and machine-learning (ML) workloads. As GPU clusters grow and short-reach links scale across dense server racks, operators need 800Gbit/s optics that deliver higher capacity within strict power and cooling limits. LiteWave800™ answers this challenge with a fully re-engineered architecture that significantly reduces energy consumption. Operating at just 1pJ/bit and consuming on
Hyperice Introduces Hypervolt 3 Line: More Powerful, Quieter, and Longer-Lasting Percussion Massage Devices10.3.2026 14:00:00 CET | Press release
Upgraded Line Includes Redesigned Head Attachments and New Carry Case for an Enhanced Warm-Up and Recovery Experience Hyperice, a high-performance wellness brand, today announced the global launch of the Hypervolt 3 line, its most advanced percussion massage technology to date. The three-device line features the Hypervolt Go 3 ($149), the Hypervolt 3 ($249), and the Hypervolt 3 Pro ($349) — achieving significant performance upgrades across the board at more accessible price points than industry competitors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310934508/en/ The Hypervolt 3 line enables users to massage away stress and tension, loosen muscle knots, maintain flexibility and range of motion, accelerate warm-up before workouts, and recover quickly after activity. Hyperice has built its reputation over the last 15 years on one guiding principle: elite-level recovery technology designed to help everyone perform and mo
Verifone and Thales Unlock Seamless Global Connectivity for Payment Terminals10.3.2026 14:00:00 CET | Press release
Thales today announced a partnership with Verifone, a global leader in payment terminal solutions, to connect Verifone’s next-generation point-of-sale (POS) terminals using Thales eSIM technology. The collaboration aims to simplify device deployment and enable secure, flexible connectivity for payment terminals worldwide; as connectivity can be provisioned, managed and updated remotely throughout the device lifecycle. By using Thales eSIM management platform, Verifone removes the need for removable SIM cards and country-specific hardware versions, significantly reducing operational complexity for manufacturers and service providers alike. At the core of this partnership is Thales’s leadership in eSIM management for large-scale connected devices, enabling remote connectivity provisioning and management, in line with the latest GSMA SGP.32 IoT specifications. These standards support secure and interoperable management of connectivity profiles, making it possible to deploy devices globall
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom